Skip to content

US · RNTX · BIOTECHNOLOGY

Rein Therapeutics Inc. (RNTX) intrinsic value and stock valuation

$0.34as of 2026-11-21 · Mkt cap 19.97M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rein Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values RNTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RNTX’s statements →

Rein Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Austin, TX 78758 reintx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-49.87M
20202025
Free cash flow
-$-19.36M
20152025
Total equity
$16.9M+6.8% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-21.93M-$-65.11M-$-20K-$-30K-$-30K
Net income-$-49.87M-$-62.88M-$-20K-$-30K-$-30K
EPSd-$-1.96M-$-3.51M-$-4.35K-$-6.61K-$-6.76K
Operating cash flow-$-19.36M-$-22.29M-$-19.81M-$-24.86M-$-23.75M
Capital expenditure$0.00$0.00$0.00$0.00-$-160K
Free cash flow-$-19.36M-$-22.29M-$-19.81M-$-24.86M-$-23.91M
Total assets$24.2M$69.2M$106M$22M$48.5M
Total debt$0.00$0.00$50K$30K$160K
Net debt-$-3.21M-$-12.87M-$-17.27M-$-5.16M-$-3.44M
Total equity$16.9M$54.4M$6.89M$18.6M$43.9M
Cash and short-term investments$3.21M$12.9M$17.3M$21.2M$45.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit-$0.00$0.00$0.00$0.00$0.00
Research and development expenses$11M$14.3M$0.00$20K$20K
Selling, general and administrative expenses$10.9M$13.9M$10K$10K$10K
Other expenses-$0.00$37M$0.00$0.00$0.00
Operating expenses$21.9M$65.1M$20K$30K$30K
Cost and expenses$21.9M$65.1M$20K$30K$30K
Interest income$0.00$400K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$60K$0.00$0.00$0.00
Ebitda-$-50.58M-$-28.05M-$-20K-$-30K-$-30K
Operating income-$-21.93M-$-65.11M-$-20K-$-30K-$-30K
Total other income/expenses, net-$-28.65M$800K$0.00$0.00$0.00
Income before tax-$-50.58M-$-64.31M-$-20K-$-30K-$-30K
Income tax expense-$-710K-$-1.54M$0.00$0.00$0.00
Net income-$-49.87M-$-62.88M-$-20K-$-30K-$-30K
Weighted average shares outstanding$25.4M$17.9M$4.6M$4.54M$4.44M
Weighted average diluted shares outstanding$25.4M$17.9M$4.6M$4.54M$4.44M
Balance sheet
20252024202320222021
Cash and short-term investments$3.21M$12.9M$17.3M$21.2M$45.9M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$4.33M$13.7M$18.3M$21.9M$48.2M
Property, plant and equipment, net$0.00$0.00$20K$110K$280K
Goodwill and intangible assets$19.8M$48.5M$85.5M$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$19.8M$55.6M$87.7M$130K$300K
Total assets$24.2M$69.2M$106M$22M$48.5M
Accounts payable$3.98M$910K$1.19M$1.72M$1.21M
Short-term debt$0.00$0.00$50K$30K$90K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$6.18M$5.75M$4.38M$3.38M$4.51M
Long-term debt$0.00$0.00$0.00$0.00$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.06M$9.1M$94.7M$0.00$70K
Capital lease obligations$0.00$0.00$50K$30K$160K
Total liabilities$7.24M$14.9M$99.1M$3.38M$4.58M
Common stock$110K$110K$90K$90K$90K
Retained earnings-$-401.27M-$-351.4M-$-288.52M-$-272.79M-$-245.46M
Accumulated other comprehensive income (loss)-$-60K-$-20K-$-60K-$-50K-$-10K
Total equity$16.9M$54.4M$6.89M$18.6M$43.9M
Total investments$0.00$0.00$0.00$16.1M$42.3M
Total debt$0.00$0.00$50K$30K$160K
Net debt-$-3.21M-$-12.87M-$-17.27M-$-5.16M-$-3.44M
Cash flow statement
20252024202320222021
Net income-$-49.87M-$-62.88M-$-15.73M-$-27.33M-$-26.16M
Depreciation and amortization$0.00$60K$120K$170K$120K
Stock-based compensation$2.22M$1.12M$1.19M$2.08M$2.26M
Change in working capital-$-860K$2.41M-$-5.38M$420K$240K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$3.06M-$-280K-$-4.98M$510K-$-390K
Net cash provided by operating activities-$-19.36M-$-22.29M-$-19.81M-$-24.86M-$-23.75M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00-$-160K
Acquisitions, net$0.00$0.00-$-100K$0.00$0.00
Net cash used for investing activities$0.00$0.00$16.2M$26.5M-$-35.92M
Common stock issued$9.76M$10.6M$0.00$0.00$55.6M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.76M$17.8M$15.8M$0.00$55.7M
Net change in cash-$-9.65M-$-4.47M$12.1M$1.59M-$-4.01M
Cash at end of period$3.21M$12.9M$17.3M$5.22M$3.62M
Operating cash flow-$-19.36M-$-22.29M-$-19.81M-$-24.86M-$-23.75M
Capital expenditure$0.00$0.00$0.00$0.00-$-160K
Free cash flow-$-19.36M-$-22.29M-$-19.81M-$-24.86M-$-23.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rein Therapeutics Inc.

        Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.

        CEO
        James Brian Windsor
        Employees
        10
        Beta
        1.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Rein Therapeutics Inc. (RNTX)?

        InvestorsCraft does not currently publish an intrinsic value for RNTX. How the IC value is calculated.

        Is RNTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for RNTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.